ClinicalTrials.gg
CompletedNCT04896385Updated Aug 5, 2025Results posted

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

A Phase 2 interventional study of Ruxolitinib cream and Vehicle Cream in Vitiligo, sponsored by Incyte Corporation. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.

Enrollment
8th of 14
60 · median 90
Started
2021
the only one that year
Phase 2
5 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
9 of 14
Incyte Corporation

Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 8th largest by enrollment, is the only one that started in 2021, is one of 5 in phase 2, and was the 6th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ruxolitinib in Vitiligo, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the Mechanism Of Action (MOA) of ruxolitinib cream in vitiligo by assessing the change in biomarkers.

03

Conditions studied

  • Vitiligo

Browse trials for

Keywords

  • Vitiligo
  • depigmenting disorder
  • topical JAK inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of nonsegmental vitiligo with depigmented areas including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, and ≥ 3 T-VASI; total body vitiligo area (facial and nonfacial) should not exceed 50% BSA.
  • At least 1 active vitiligo lesion (eg, such as confetti lesion, trichrome appearance, pinkish rim, or other evidence of inflammatory activity) at the site for skin .
  • Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.

Exclusion criteria

Exclusion Criteria

  • No pigmented hair within any of the vitiligo areas on the face.
  • Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).
  • Used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas except hydroquinone.
  • Any other skin disease that, in the opinion of the investigator, would interfere with the study medication application or study assessments.
  • Conditions at baseline that would interfere with evaluation of vitiligo.
  • Use of any protocol-defined treatments within the indicated before baseline.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Ruxolitinib cream

    Ruxolitinib cream will be administered twice a day (BID) for 24 weeks

    Drug: Ruxolitinib cream

  • Placebo comparator
    Vehicle Cream

    Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.

    Drug: Vehicle Cream

Interventions

  • Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

    Also known as: INCB018424 cream

  • DrugVehicle Cream

    Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24

    Baseline was defined as the last non-missing measurement obtained on or before the first application of study drug. Percentage change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] / Baseline value)\*100.

    Time frame: Baseline; Week 4, Week 12, and Week 24

Secondary outcomes

  1. Correlation of Key Skin Inflammatory Biomarkers of Vitiligo in Target Lesions to Efficacy Readouts

    Clinical scores (facial Vitiligo Area Scoring Index \[F-VASI\] and total body Vitiligo Area Scoring Index \[T-VASI\]) were evaluated for correlation with skin CXCL10 levels.

    Time frame: Baseline, Week 12, and Week 24

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

    Time frame: from the time of Informed Consent Form signing until the start of the Treatment-Extension Period or 30 days after the last application of study drug during the Double-Blind Period (up to Week 24 + 30 days)

  3. Number of Participants With TEAEs During the Treatment-Extension Period

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

    Time frame: from the completion of the Week 24 assessments until at least 30 days after the last application of study drug at Week 52 + 30 days

  4. Number of Participants With a Grade 3 or Higher TEAE During the Double-Blind Period

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. AE severity was assessed per the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated; Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living; Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4: life-threatening consequences; urgent treatment indicated; Grade 5: fatal.

    Time frame: from the time of Informed Consent Form signing until the start of the Treatment-Extension Period or 30 days after the last application of study drug during the Double-Blind Period (up to Week 24 + 30 days)

  5. Number of Participants With a Grade 3 or Higher TEAE During the Treatment-Extension Period

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. AE severity was assessed per the CTCAE, version 5.0: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated; Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living; Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4: life-threatening consequences; urgent treatment indicated; Grade 5: fatal.

    Time frame: from the completion of the Week 24 assessments until at least 30 days after the last application of study drug at Week 52 + 30 days

07

Results

Posted Dec 7, 2023

Participant flow

24-Week Double-Blind Period
Participant flow — 24-Week Double-Blind Period
MilestoneDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Started411900
Completed371400
Not completed4500
Withdrew: Lost to follow-up2300
Withdrew: Withdrawal by subject2200
28-Week Treatment-Extension Period
Participant flow — 28-Week Treatment-Extension Period
MilestoneDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Started003714
Completed00279
Not completed00105
Withdrew: Lost to follow-up0052
Withdrew: Withdrawal by subject0011
Withdrew: Participant refused safety follow-up0032
Withdrew: Pregnancy0010

Outcome measures

PrimaryPercentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24

Baseline was defined as the last non-missing measurement obtained on or before the first application of study drug. Percentage change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] / Baseline value)\*100.

Time frame:
Baseline; Week 4, Week 12, and Week 24
Reported as:
Mean · percent change
Percentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24
percent changeDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Week 4-20.93 ± 36.2168.13 ± 52.491——
Week 12-18.33 ± 40.03521.13 ± 70.690——
Week 24-12.92 ± 46.14622.17 ± 68.893——
SecondaryCorrelation of Key Skin Inflammatory Biomarkers of Vitiligo in Target Lesions to Efficacy Readouts

Clinical scores (facial Vitiligo Area Scoring Index \[F-VASI\] and total body Vitiligo Area Scoring Index \[T-VASI\]) were evaluated for correlation with skin CXCL10 levels.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Number · correlation coefficient
Correlation of Key Skin Inflammatory Biomarkers of Vitiligo in Target Lesions to Efficacy Readouts
correlation coefficientDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
F-VASI-0.340.15
T-VASI-0.430.02
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID · repeated measures correlation · p = 0.004
  • Double-Blind Period: Vehicle Cream BID · repeated measures correlation · p = 0.41
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID · repeated measures correlation · p = 0.0002
  • Double-Blind Period: Vehicle Cream BID · repeated measures correlation · p = 0.91
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

Time frame:
from the time of Informed Consent Form signing until the start of the Treatment-Extension Period or 30 days after the last application of study drug during the Double-Blind Period (up to Week 24 + 30 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period
ParticipantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period197
SecondaryNumber of Participants With TEAEs During the Treatment-Extension Period

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

Time frame:
from the completion of the Week 24 assessments until at least 30 days after the last application of study drug at Week 52 + 30 days
Reported as:
Count of participants · Participants
Number of Participants With TEAEs During the Treatment-Extension Period
ParticipantsTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Number of Participants With TEAEs During the Treatment-Extension Period123
SecondaryNumber of Participants With a Grade 3 or Higher TEAE During the Double-Blind Period

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. AE severity was assessed per the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated; Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living; Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4: life-threatening consequences; urgent treatment indicated; Grade 5: fatal.

Time frame:
from the time of Informed Consent Form signing until the start of the Treatment-Extension Period or 30 days after the last application of study drug during the Double-Blind Period (up to Week 24 + 30 days)
Reported as:
Count of participants · Participants
Number of Participants With a Grade 3 or Higher TEAE During the Double-Blind Period
ParticipantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Number of Participants With a Grade 3 or Higher TEAE During the Double-Blind Period10
SecondaryNumber of Participants With a Grade 3 or Higher TEAE During the Treatment-Extension Period

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. AE severity was assessed per the CTCAE, version 5.0: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated; Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living; Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4: life-threatening consequences; urgent treatment indicated; Grade 5: fatal.

Time frame:
from the completion of the Week 24 assessments until at least 30 days after the last application of study drug at Week 52 + 30 days
Reported as:
Count of participants · Participants
Number of Participants With a Grade 3 or Higher TEAE During the Treatment-Extension Period
ParticipantsTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Number of Participants With a Grade 3 or Higher TEAE During the Treatment-Extension Period01

Adverse events

Collected over from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 52 + 30 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib Cream 1.5% BID0/55 (0%)1/55 (1.8%)10/55 (18.2%)
Vehicle Cream BID0/19 (0%)0/19 (0%)7/19 (36.8%)
Most frequent serious events
Most frequent serious events
EventRuxolitinib Cream 1.5% BIDVehicle Cream BID
Acute coronary syndromeCardiac disorders1/550/19
Most frequent other events
Most frequent other events
EventRuxolitinib Cream 1.5% BIDVehicle Cream BID
COVID-19Infections and infestations9/552/19
Application site exfoliationGeneral disorders1/551/19
Dermatitis contactSkin and subcutaneous tissue disorders0/551/19
GastroenteritisInfections and infestations0/551/19
HydroceleCongenital, familial and genetic disorders0/551/19
Seborrhoeic keratosisNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/551/19
Urinary tract infectionInfections and infestations0/551/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean45.1 ± 12.7343.7 ± 13.1644.7 ± 12.77
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Female18826
Male231134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Hispanic or Latino8412
Not Hispanic or Latino301444
Unknown or Not Reported314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
White/Caucasian251338
Black/African-American426
Asian538
Native Hawaiian/Pacific Islander101
Not Reported505
South Asian101
Middle Eastern011
Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an immune biomarker
Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an immune biomarker(nanograms per Liter (ng/L))Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean600.066 ± 959.3097415.471 ± 177.4902542.778 ± 804.0389
08

Study locations

13 sites
  • First Oc Dermatology
    Fountain Valley, California 92708, United States
  • UC Irvine
    Irvine, California 92697, United States
  • George Washington Medical Faculty Associates
    Washington D.C., District of Columbia 20037, United States
  • Suny Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Dermatology Specialists of Spokane
    Spokane, Washington 99202, United States
  • Dermatology Research Institute
    Calgary, Alberta T1Y 0B4, Canada
  • Simcoderm Medical and Surgical Dermatology Center
    Barrie, Ontario L4M 7G1, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P 1X2, Canada
  • JRB Research Inc
    Ottawa, Ontario K1H 7X8, Canada
  • Hopital Saint Andre
    Bordeaux, 33000, France
  • Centre Hospitalier Universitaire Henri Mondor
    Créteil, 94010, France
  • Hopital Archet 2 Derm Dept
    Nice, 06200, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Nov 2022, 16 months.

Results were first posted in Dec 2023, 1 year after primary completion.

Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2021
First posted
May 21, 2021
StartActual
Jun 23, 2021
Primary completionActual
Nov 17, 2022
CompletionActual
Jul 10, 2023
Results first posted
Dec 7, 2023
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04896385
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
May 21, 2021
Start date
Jun 23, 2021
Primary completion
Nov 17, 2022
Completion
Jul 10, 2023
Results posted
Dec 7, 2023
Last update
Aug 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion